Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Completed · Phase 3

Conditions studied: Atopic Dermatitis

In brief

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Key facts

Study ID
NCT04392154
Run by
Eli Lilly and Company
People needed
1153
Starts
2020-06-15
Expected to finish
2025-04-22
Last updated by the study team
2025-11-05

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.